Most HAE Patients Treated With Donidalorsen for Year Attack Free
Donidalorsen, a small molecule therapy being developed by Ionis Pharmaceuticals, continues to be safe and to prevent swelling attacks when taken for up to one year by people with hereditary angioedema (HAE), trial data show. The open-label extension study (NCT04307381) is ongoing in patients who completed a placebo-controlled…